Analysts’ Weekly Ratings Updates for STADA Arzneimittel (SAZ)

A number of research firms have changed their ratings and price targets for STADA Arzneimittel (ETR: SAZ):

  • 12/20/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at Nord/LB. They now have a “sell” rating on the stock.
  • 12/20/2017 – STADA Arzneimittel was given a new €66.25 ($78.87) price target on by analysts at Commerzbank Ag. They now have a “sell” rating on the stock.
  • 12/20/2017 – STADA Arzneimittel was given a new €89.00 ($105.95) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock.
  • 12/20/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at Warburg Research. They now have a “sell” rating on the stock.
  • 11/29/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at Nord/LB. They now have a “sell” rating on the stock.
  • 11/10/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at S&P Global. They now have a “sell” rating on the stock.
  • 11/10/2017 – STADA Arzneimittel was given a new €82.00 ($97.62) price target on by analysts at Independent Research GmbH. They now have a “neutral” rating on the stock.
  • 11/10/2017 – STADA Arzneimittel was given a new €74.40 ($88.57) price target on by analysts at Warburg Research. They now have a “sell” rating on the stock.

Shares of STADA Arzneimittel AG (SAZ) traded up €0.30 ($0.36) during trading on Friday, hitting €88.00 ($104.76). The company’s stock had a trading volume of 42,966 shares, compared to its average volume of 58,412. STADA Arzneimittel AG has a fifty-two week low of €46.31 ($55.13) and a fifty-two week high of €89.21 ($106.20). The firm has a market capitalization of $5,470.00 and a PE ratio of 57.89.

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.

Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit